Negative
●
Proactive Investors
●
2 months ago
Novo Nordisk (NYSE:NVO) has received a downgrade from Deutsche Bank, with analysts lowering their target price as midterm growth concerns and pipeline issues mount. The shares dropped 2.52% to DKK 297.25 as the broker adjusted its rating to 'sell', moving down from a previous 'hold' view following the drugmaker's mixed second-quarter update.